Songlin Du1, Jianwei Tian2, Zhiwen Xiao2, Zhiwen Luo1, Tong Lin2, Shaoyi Zheng1, Jun Ai2. 1. Department of Cardiovascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. 2. State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Abstract
BACKGROUND: Human alpha 1-antitrypsin (A1AT) is involved in the pathophysiological process underlying ischemic acute kidney injury (AKI). To test the hypothesis that serum A1AT (sA1AT) is a predictor for severe AKI after cardiopulmonary bypass (CPB), we conducted a prospective cohort study in 201 patients undergoing cardiac surgery. METHODS: We collected blood and urine samples, and analyzed the sA1AT and other injury biomarkers during the perioperative period. Severe AKI is defined as Kidney Disease Improving Global Outcomes (KDIGO) stage 2 or 3, and overall AKI is defined as KDIGO stage 1, 2, or 3. RESULTS: Ninety-one (45.3%) patients developed overall AKI, and 22 (10.9%) among them developed severe AKI after operation. sA1AT level spiked 2 hours after surgery in patients who subsequently developed severe AKI, while serum creatinine peaked 12 hours after operation. Higher postoperative sA1AT independently correlated to the development of severe AKI [OR, 1.54 (1.17-2.03); P=0.002]. The highest quartile of postoperative sA1AT level was associated with 6-fold higher hazards of severe AKI compared to the lowest quartile. Higher sA1AT levels were correlated with longer stays in the intensive care unit and the hospital. For predicting severe AKI, the AUC of sA1AT 2 hours after CPB reached 0.814. After combining with urine T cell immunoglobulin mucin-1 and clinical model, the AUC improved to 0.923. CONCLUSIONS: In summary, sA1AT is a valuable predictor of severe AKI development and prolonged ICU and hospital stays in patients after cardiac surgery. 2019 Journal of Thoracic Disease. All rights reserved.
BACKGROUND: Human alpha 1-antitrypsin (A1AT) is involved in the pathophysiological process underlying ischemic acute kidney injury (AKI). To test the hypothesis that serum A1AT (sA1AT) is a predictor for severe AKI after cardiopulmonary bypass (CPB), we conducted a prospective cohort study in 201 patients undergoing cardiac surgery. METHODS: We collected blood and urine samples, and analyzed the sA1AT and other injury biomarkers during the perioperative period. Severe AKI is defined as Kidney Disease Improving Global Outcomes (KDIGO) stage 2 or 3, and overall AKI is defined as KDIGO stage 1, 2, or 3. RESULTS: Ninety-one (45.3%) patients developed overall AKI, and 22 (10.9%) among them developed severe AKI after operation. sA1AT level spiked 2 hours after surgery in patients who subsequently developed severe AKI, while serum creatinine peaked 12 hours after operation. Higher postoperative sA1AT independently correlated to the development of severe AKI [OR, 1.54 (1.17-2.03); P=0.002]. The highest quartile of postoperative sA1AT level was associated with 6-fold higher hazards of severe AKI compared to the lowest quartile. Higher sA1AT levels were correlated with longer stays in the intensive care unit and the hospital. For predicting severe AKI, the AUC of sA1AT 2 hours after CPB reached 0.814. After combining with urine T cell immunoglobulin mucin-1 and clinical model, the AUC improved to 0.923. CONCLUSIONS: In summary, sA1AT is a valuable predictor of severe AKI development and prolonged ICU and hospital stays in patients after cardiac surgery. 2019 Journal of Thoracic Disease. All rights reserved.
Authors: Seung Seok Han; Nara Shin; Seon Ha Baek; Shin Young Ahn; Dong Ki Kim; Sejoong Kim; Ho Jun Chin; Dong-Wan Chae; Ki Young Na Journal: Am Heart J Date: 2015-01-06 Impact factor: 4.749
Authors: Hjalmar R Bouma; Hubert E Mungroop; A Fred de Geus; Daniel D Huisman; Maarten W N Nijsten; Massimo A Mariani; Thomas W L Scheeren; Johannes G M Burgerhof; Robert H Henning; Anne H Epema Journal: Ann Thorac Surg Date: 2018-03-01 Impact factor: 4.330
Authors: Catherine D Krawczeski; Stuart L Goldstein; Jessica G Woo; Yu Wang; Nuntawan Piyaphanee; Qing Ma; Michael Bennett; Prasad Devarajan Journal: J Am Coll Cardiol Date: 2011-11-22 Impact factor: 24.094
Authors: Danny Jonigk; Mariam Al-Omari; Lavinia Maegel; Meike Müller; Nicole Izykowski; Jaewoo Hong; Kwangwon Hong; Soo-Hyun Kim; Martina Dorsch; Ravi Mahadeva; Florian Laenger; Hans Kreipe; Armin Braun; Galit Shahaf; Eli C Lewis; Tobias Welte; Charles A Dinarello; Sabina Janciauskiene Journal: Proc Natl Acad Sci U S A Date: 2013-08-23 Impact factor: 11.205
Authors: T Kaufeld; K A Foerster; T Schilling; J T Kielstein; J Kaufeld; M Shrestha; H G Haller; A Haverich; B M W Schmidt Journal: BMC Nephrol Date: 2018-07-04 Impact factor: 2.388
Authors: Jason G E Zelt; Lisa M Mielniczuk; Peter P Liu; Jean-Yves Dupuis; Sharon Chih; Ayub Akbari; Louise Y Sun Journal: J Clin Med Date: 2018-12-12 Impact factor: 4.241